Joshua T. Schiffer

7.4k total citations
133 papers, 3.6k citations indexed

About

Joshua T. Schiffer is a scholar working on Epidemiology, Infectious Diseases and Virology. According to data from OpenAlex, Joshua T. Schiffer has authored 133 papers receiving a total of 3.6k indexed citations (citations by other indexed papers that have themselves been cited), including 67 papers in Epidemiology, 59 papers in Infectious Diseases and 35 papers in Virology. Recurrent topics in Joshua T. Schiffer's work include Herpesvirus Infections and Treatments (44 papers), Cytomegalovirus and herpesvirus research (31 papers) and SARS-CoV-2 and COVID-19 Research (29 papers). Joshua T. Schiffer is often cited by papers focused on Herpesvirus Infections and Treatments (44 papers), Cytomegalovirus and herpesvirus research (31 papers) and SARS-CoV-2 and COVID-19 Research (29 papers). Joshua T. Schiffer collaborates with scholars based in United States, South Africa and Canada. Joshua T. Schiffer's co-authors include Lawrence Corey, Anna Wald, Daniel B. Reeves, Bryan T. Mayer, Keith R. Jerome, E. Fabián Cardozo-Ojeda, Ashish Goyal, David A. Swan, Stacy Selke and Amalia Magaret and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Investigation.

In The Last Decade

Joshua T. Schiffer

125 papers receiving 3.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joshua T. Schiffer United States	36	1.9k	1.3k	746	611	489	133	3.6k
Philippa C. Matthews United Kingdom	34	1.6k 0.8×	1.6k 1.2×	1.0k 1.4×	800 1.3×	512 1.0×	141	4.1k
Prasert Auewarakul Thailand	29	2.3k 1.2×	1.8k 1.4×	559 0.7×	732 1.2×	728 1.5×	157	4.0k
Annemarie Berger Germany	35	1.8k 0.9×	1.7k 1.3×	736 1.0×	205 0.3×	401 0.8×	130	3.7k
Mark Pandori United States	31	964 0.5×	1.8k 1.3×	1.0k 1.4×	376 0.6×	461 0.9×	83	3.3k
Katja C. Wolthers Netherlands	39	2.7k 1.4×	3.9k 2.9×	693 0.9×	963 1.6×	603 1.2×	134	6.6k
Vivek Naranbhai United States	28	682 0.4×	2.4k 1.8×	390 0.5×	1.1k 1.9×	918 1.9×	78	4.0k
Renu B. Lal United States	40	1.4k 0.7×	1.7k 1.3×	2.0k 2.6×	1.5k 2.5×	527 1.1×	144	4.4k
Ian J. Amanna United States	22	896 0.5×	960 0.7×	510 0.7×	1.3k 2.1×	716 1.5×	42	3.0k
Ella Mendelson Israel	45	2.0k 1.0×	3.6k 2.7×	262 0.4×	603 1.0×	823 1.7×	261	6.3k
Daniel R. Lucey United States	30	1.1k 0.6×	1.3k 1.0×	1.3k 1.7×	1.7k 2.8×	347 0.7×	76	4.2k

Countries citing papers authored by Joshua T. Schiffer

Since Specialization

Citations

This map shows the geographic impact of Joshua T. Schiffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joshua T. Schiffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joshua T. Schiffer more than expected).

Fields of papers citing papers by Joshua T. Schiffer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joshua T. Schiffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joshua T. Schiffer. The network helps show where Joshua T. Schiffer may publish in the future.

Co-authorship network of co-authors of Joshua T. Schiffer

This figure shows the co-authorship network connecting the top 25 collaborators of Joshua T. Schiffer. A scholar is included among the top collaborators of Joshua T. Schiffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joshua T. Schiffer. Joshua T. Schiffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wagoner, Jessica, Rana Abdelnabi, Jennifer Hyde, et al.. (2025). Combinations of approved oral nucleoside analogues confer potent suppression of alphaviruses in vitro and in vivo. Antiviral Research. 239. 106186–106186.

Owens, Katherine, et al.. (2024). A unifying model to explain frequent SARS-CoV-2 rebound after nirmatrelvir treatment and limited prophylactic efficacy. Nature Communications. 15(1). 5478–5478. 7 indexed citations

Xu, Shuang, E. Fabián Cardozo-Ojeda, Ashish Goyal, et al.. (2024). Two-way pharmacodynamic modeling of drug combinations and its application to pairs of repurposed Ebola and SARS-CoV-2 agents. Antimicrobial Agents and Chemotherapy. 68(4). e0101523–e0101523. 2 indexed citations

Kim, Jin‐Ju, Eun-Jeong Yang, Joshua T. Schiffer, et al.. (2024). Ezetimibe Enhances Lipid Droplet and Mitochondria Contact Formation, Improving Fatty Acid Transfer and Reducing Lipotoxicity in Alport Syndrome Podocytes. International Journal of Molecular Sciences. 25(23). 13134–13134. 4 indexed citations

Lim, Fang Yun, Sooyoung Kim, Louise E. Kimball, et al.. (2023). High-frequency home self-collection of capillary blood correlates IFI27 expression kinetics with SARS-CoV-2 viral clearance. Journal of Clinical Investigation. 133(23). 3 indexed citations

Reeves, Daniel B., Christian Gaebler, Thiago Y. Oliveira, et al.. (2023). Impact of misclassified defective proviruses on HIV reservoir measurements. Nature Communications. 14(1). 4186–4186. 19 indexed citations

Swan, David A., Morgane Rolland, Joshua T. Herbeck, Joshua T. Schiffer, & Daniel B. Reeves. (2022). Evolution during primary HIV infection does not require adaptive immune selection. Proceedings of the National Academy of Sciences. 119(7). 2 indexed citations

Wagoner, Jessica, Tien-Ying Hsiang, Aleksandr Ianevski, et al.. (2022). Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2. Microbiology Spectrum. 10(5). e0333122–e0333122. 34 indexed citations

Zhao, Lue Ping, Terry P. Lybrand, Peter B. Gilbert, et al.. (2021). Tracking SARS-CoV-2 Spike Protein Mutations in the United States (January 2020—March 2021) Using a Statistical Learning Strategy. Viruses. 14(1). 9–9. 9 indexed citations

10.

Byrne, Catherine, Christine Johnston, Jackson Orem, et al.. (2021). Examining the dynamics of Epstein-Barr virus shedding in the tonsils and the impact of HIV-1 coinfection on daily saliva viral loads. PLoS Computational Biology. 17(6). e1009072–e1009072. 13 indexed citations

11.

White, Judith M., Joshua T. Schiffer, Rachel Bender Ignacio, et al.. (2021). Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses. mBio. 12(6). e0334721–e0334721. 42 indexed citations

12.

Cardozo-Ojeda, E. Fabián, Elizabeth R. Duke, Christopher W. Peterson, et al.. (2021). Thresholds for post-rebound SHIV control after CCR5 gene-edited autologous hematopoietic cell transplantation. eLife. 10. 13 indexed citations

13.

Matrajt, Laura, et al.. (2021). Quantifying the Impact of Lifting Community Nonpharmaceutical Interventions for COVID-19 During Vaccination Rollout in the United States. Open Forum Infectious Diseases. 8(7). ofab341–ofab341. 4 indexed citations

14.

Waghmare, Alpana, Elizabeth M. Krantz, E Chung, et al.. (2020). Reliability of Self-Sampling for Accurate Assessment of Respiratory Virus Viral and Immunologic Kinetics. The Journal of Infectious Diseases. 226(2). 278–286. 9 indexed citations

15.

Duke, Elizabeth R., Brian D. Williamson, Bhavesh Borate, et al.. (2020). CMV viral load kinetics as surrogate endpoints after allogeneic transplantation. Journal of Clinical Investigation. 131(1). 40 indexed citations

16.

Antar, Annukka A.R., Katharine M. Jenike, Sunyoung Jang, et al.. (2020). Longitudinal study reveals HIV-1–infected CD4+ T cell dynamics during long-term antiretroviral therapy. Journal of Clinical Investigation. 130(7). 3543–3559. 54 indexed citations

17.

Cao, Shijie, Claire Levy, Sean M. Hughes, et al.. (2019). Hybrid nanocarriers incorporating mechanistically distinct drugs for lymphatic CD4 ⁺ T cell activation and HIV-1 latency reversal. Science Advances. 5(3). eaav6322–eaav6322. 34 indexed citations

18.

Huang, Yunda, Shelly Karuna, Lindsay N. Carpp, et al.. (2018). Modeling cumulative overall prevention efficacy for the VRC01 phase 2b efficacy trials. Human Vaccines & Immunotherapeutics. 14(9). 2116–2127. 17 indexed citations

19.

Looker, Katharine J, Jocelyn Elmes, Sami L. Gottlieb, et al.. (2017). Effect of HSV-2 infection on subsequent HIV acquisition: an updated systematic review and meta-analysis. The Lancet Infectious Diseases. 17(12). 1303–1316. 194 indexed citations

20.

Alsallaq, Ramzi, Joshua T. Schiffer, Ira M. Longini, et al.. (2010). Population Level Impact of an Imperfect Prophylactic Vaccine for Herpes Simplex Virus-2. Sexually Transmitted Diseases. 37(5). 290–297. 34 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact